# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Lamictal 50 mg chewable/dispersible tablets

### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each Lamictal 50 mg chewable/dispersible tablet contains 50 mg lamotrigine.

For the full list of excipients, see section 6.1.

## **3 PHARMACEUTICAL FORM**

Chewable/dispersible tablet.

Product imported from Spain and Germany

White to off-white square tablet with rounded corners with a blackcurrant odour, marked "GSCX7" on one side and "50" on the other. The tablets may be slightly mottled.

### **4 CLINICAL PARTICULARS**

As per PA1077/061/008

### **5 PHARMACOLOGICAL PROPERTIES**

As per PA1077/061/008

## **6 PHARMACEUTICAL PARTICULARS**

#### 6.1 List of excipients

Calcium carbonate Low-substituted hydroxypropyl cellulose Aluminium magnesium silicate Sodium starch glycolate (Type A) Povidone K30 Saccharin sodium Magnesium stearate Blackcurrant flavour

#### 6.2 Incompatibilities

Not applicable.

## 6.3 Shelf life

The shelf life expiry date of this product is the date shown on the container and outer carton of the product as marketed in the country of origin.

#### 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

#### 6.5 Nature and contents of container

Blister packs of 56 chewable/dispersible tablets.

26 April 2023

CRN00DHP4

## 6.6 Special precautions for disposal

No special requirements for disposal.

## 7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/443/002

### 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14<sup>th</sup> September 2012 Last updated: April 2016 Last updated: September 2018 Last updated: May 2019

#### **10 DATE OF REVISION OF THE TEXT**

April 2023